NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

鈣離子通道拮抗劑的全球市場 (2020-2027年)

Global Calcium Channel Blocker Market - 2020-2027

出版商 DataM Intelligence 商品編碼 977293
出版日期 按訂單生產 內容資訊 英文
商品交期: 請詢問到貨日
價格
鈣離子通道拮抗劑的全球市場 (2020-2027年) Global Calcium Channel Blocker Market - 2020-2027
出版日期: 按訂單生產內容資訊: 英文
簡介

全球鈣離子通道拮抗劑的成長受到新興市場推動,對研究開發的巨額的投資成為該市場的成長要素。再加上醫療保健基礎設施的改善需求高漲預計帶動市場。

心血管疾病的盛行率的上升及人們的生活方式的變化,預計推動鈣離子通道拮抗劑市場成長。高血壓,是心臟病相關的主要原因之一。根據世界衛生組織 (WHO) ,在全球約有11億3000萬人患高血壓病。再加上心血管疾病是主要的死因之一,2016年約有1,790萬人死亡。鈣拮抗劑,對該適應症有效。

對有焦慮症或躁鬱症的人的支援高漲,預計也促進市場成長。

另一方面,水腫,頭痛,心搏過速,便秘等鈣離子通道拮抗劑相關的副作用,有阻礙該市場的整體需求的可能性。

本報告提供全球鈣離子通道拮抗劑市場相關調查,市場概要,各市場區隔及各地區的市場分析與預測,競爭情形分析,並提供主要企業簡介等資訊。。

目錄

第1章 全球鈣離子通道拮抗劑市場:調查手法、範圍

  • 調查手法
  • 調查目的、調查範圍

第2章 全球鈣離子通道拮抗劑市場:市場定義、概要

第3章 全球鈣離子通道拮抗劑市場:摘要整理

  • 市場明細:各醫藥品分類
  • 市場明細:各給藥途徑
  • 市場明細:各流通管道
  • 市場明細:各地區

第4章 全球鈣離子通道拮抗劑市場:市場動態

  • 影響市場的要素
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 影響分析

第5章 全球鈣離子通道拮抗劑市場:產業分析

  • 波特的五力分析
  • 供應鏈分析
  • 價格分析
  • 法規分析
  • 償付分析
  • 未滿足需求

第6章 全球鈣離子通道拮抗劑市場:COVID-19分析

  • 市場上Covid-19分析
    • COVID-19:之前的市場情境
    • COVID-19:目前市場情境
    • COVID-19:之後或未來情境
  • Covid-19的價格動態
  • 需求與供給的頻譜
  • 大流行時的市場相關的政府舉措
  • 製造商策略性舉措
  • 結論

第7章 全球鈣離子通道拮抗劑市場:各醫藥品分類

  • 簡介
  • 市場規模分析、與前一年同期比較成長分析(%):各醫藥品分類
  • 市場魅力指數:各醫藥品分類
    • Nondihydropyridines
    • Benzothizepine
    • Phenylalkylamine
    • 其他

第8章 全球鈣離子通道拮抗劑市場:各給藥途徑

  • 簡介
  • 市場規模分析、與前一年同期比較成長分析(%):各給藥途徑
  • 市場魅力指數:各給藥途徑
    • 口服
    • 非口服

第9章 全球鈣離子通道拮抗劑市場:各流通管道

  • 簡介
  • 市場規模分析、與前一年同期比較成長分析(%):各流通管道
  • 市場魅力指數:各流通管道
    • 醫院藥局
    • 藥局
    • 其他

第10章 全球鈣離子通道拮抗劑市場:各地區

  • 簡介
  • 市場規模分析、與前一年同期比較成長分析(%):各地區
  • 市場魅力指數:各地區
  • 北美
    • 簡介
    • 主要地區具體動態
    • 市場規模分析、與前一年同期比較成長分析(%):各醫藥品分類
    • 市場規模分析、與前一年同期比較成長分析(%):各給藥途徑
    • 市場規模分析、與前一年同期比較成長分析(%):各流通管道
    • 市場規模分析、與前一年同期比較成長分析(%):各國
  • 歐洲
  • 南美
  • 亞太地區
  • 中東、非洲

第11章 全球鈣離子通道拮抗劑市場:競爭情形

  • 競爭模式
  • 市場定位/佔有率分析
  • 合併和收購分析

第12章 全球鈣離子通道拮抗劑市場:企業簡介

  • ClearSynth
  • GlaxoSmithKline Plc.,
  • Pfizer Inc.
  • AbMole Bioscience
  • Lupin Pharmaceuticals, Inc.
  • Silvergate Pharmaceuticals Inc.
  • Novartis AG
  • Covis Pharma BV
  • Arbor Pharmaceuticals LLC
  • Janssen Global Services, LLC

第13章 重要考察

第14章 DataM

  • 附錄
  • 關於本公司、服務
  • 諮詢方式
目錄

Market Overview

The global calcium channel blocker market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).

Calcium channel blockers are medications which are used control high blood pressure, chest pain and arrhythmia. They are available through prescription and work by relaxing blood vessels and increase the blood and oxygen supply to the heart. This reduces the workload of the heart. It can be prescribed by itself or in combination with other medications to treat high blood pressure and angina. There are a few different types of calcium channel blockers and each works in a slightly different way. These are highly effective as compared to beta blockers in lowering the risk of cardiovascular mortality. They help to reduce the amount of calcium that goes into the cardiac muscle cells and cause them to relax. Changing lifestyle of people across all regions led to an increase in the number of stress related disease, which is a major factor, which in turn is anticipated to drive the calcium channel blocker market.

Market Dynamics

The global calcium channel blocker growth is driven by the emerging markets and huge investment in research and development are the factors responsible for the growth of this market. Moreover, the rising demand for improved healthcare infrastructure are expected to drive the market.

The increasing prevalence rate of cardiovascular diseases, is expected to drive the growth in the forecast period

The increasing prevalence rate of cardiovascular diseases and changing lifestyle of people is expected to boost the calcium channel blocker market growth. Hypertension often referred as the elevated blood pressure is one of the major causes associated with heart diseases. According to World Health Organization, approximately 1.13 billion of people globally have hypertension. Furthermore, cardiovascular diseases are one of the leading causes of the death and around 17.9 million people died in 2016 due to it. Calcium antagonist are known to be effective against this indication. Thus, the demand has been steadily growing for this market for better management of the cardiovascular diseases. These factors are driving the growth of the market in the forecast period.

Rising assistance to people with anxiety disorders or bipolar disorder expected to drive the market growth

A smaller population of people who do not have a heart condtiion could also benefit from calcium channel blockers. There is some indication they may work as mood stabilizers and be of assistance to people with anxiety disorders or bipolar disorder. The latter is particularly under investigation because some calcium channel blocker may be somewhat safer to administer to pregnant women than are most traditional mood stabilizers or antipsychotics. A few calcium channel blocker are useful in the treatment of migraine headaches, too. There are quite a few drugs that are considered calcium channel blockers and each may have its own profile of side effects, risks, and benefits. Some medications that make this list include verapamil, amlodipine and dilatiazem. Others are nifedipine, felodipine, and nicardipine. There are still more calcium channel blockers and others might arrive on the market if they are considered improvement on the present supply.

Major side effects of drugs is likely to hinder the market growth

On the contrary, side effects related to calcium channel blockers such as edema, headache, rapid heart rate, and constipation are likely to hamper the overall demand for calcium channel blocker market.

The Wall Street Journal (winter, l996) reported that patients who took calcium channel blockers had 60% more chance of dying of a heart attack. This is because calcium channel blocker drugs take a system that is functioning poorly and damage it even more. Many previous studies have associated calcium channel blockers with increased heart attacks, increased risk of breast cancer, increased suicide risk, and increased gastrointestinal bleeding. Short-acting versions of these drugs have been previously shown to be dangerous and now long-acting versions are being shown to be possibly dangerous as well. These factors restrict the market growth.

COVID-19 Impact Analysis

As the COVID-19 outbreak continues to endanger global health and hamper the world economy, there are concerns and reconsiderations for medication taken by patients with cardiometabolic disorders as they are more vulnerable to COVID-19. It has been widely observed that patients with existing cardiovascular diseases experience higher rates of complications due to COVID-19. Specifically, it has been found that patients with hypertension, diabetes, and other comorbidities are at higher risk of death from the virus. During the widespread COVID-19 pandemic, there have been worries about the potential of certain blood pressure medications such as calcium channel blocker. he Centers for Disease Control and Prevention (CDC) and the European Society of Cardiology (ESC) and its council on hypertension have released position statements saying "we should not be jumping to conclusions and should not be withholding life-saving therapies from patients." More importantly, two very recent studies attest that blood pressure drugs do not increase coronavirus risk. These factors are driving the market growth in the forecast period.

Segment Analysis

By drug class, the calcium channel blockeris market is classified into dihydropyridine (amlodipine (Norvasc), nifedipine (Procardia, Adalat), felodipine (Plendil)), nondihydropyridines (verapamil (Calan, Isoptin), diltiazem (Cardizem)), benzothizepine, phenylalkylamine and others.

Dihydropyridines segment is expected to grow at the fastest CAGR during the forecast period (2020-2027)

Dihydropyridines target a specific type of calcium channel in the body. They cause the blood vessels to widen, lowering blood pressure. Dihydropyridine is known to exhibit more vasodilation and less negative ionotropic effect in sinoatrial and atrioventricular nodes. Amlodipine is the most common type of dihydropyridines.

Amlodipine is used with or without other medications to treat high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. Amlodipine belongs to a class of drugs known as calcium channel blockers. It works by relaxing blood vessels so blood can flow more easily.Amlodipine is also used to prevent certain types of chest pain (angina). It may help to increase your ability to exercise and decrease the frequency of angina a

Nifedipine is in a group of drugs called calcium channel blockers. It works by relaxing the muscles of your heart and blood vessels. Nifedipine is used to treat hypertension (high blood pressure) and angina (chest pain). Nifedipine may also be used for purposes not listed in this medication guide. However, Some tablet forms of nifedipine are made with a shell that is not absorbed or melted in the body. Part of the tablet shell may appear in your stool. This is a normal side effect of nifedipine and will not make the medication less effective.

Felodipine is a calcium channel blocker that is used to treat hypertension (high blood pressure) in adults. Lowering blood pressure can help lower your risk of a stroke or heart attack. Felodipine inhibits the influx of extracellular calcium ions into myocardial and vascular smooth muscle cells, causing dilatation of the main coronary and systemic arteries and decreasing myocardial contractility. This agent also inhibits the drug efflux pump P-glycoprotein which is overexpressed in some multi-drug resistant tumors and may improve the efficacy of some antineoplastic agents.

On the basis of distribution channel, the calcium channel blockeris classified into hospital pharmacy, pharmacy stores, others.

The hospital pharmacy are expected to dominate the calcium channel blocker market during the forecast period

The hospital pharmacies held the largest share in the calcium channel blocker market. This is mainly owing to increasing number of patients suffering from conditions which are treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, growing number of hospitals along with adequate reimbursement policies is also contributing to the growth of this segment.

Geographical Analysis

North America region holds the largest market share global Calcium Channel Blocker

North America expected to hold a major market share in the global calcium Channel blocker market due to changing lifestyle among people and increasing prevalence rate of cardiovascular diseases. The adoption of sedentary lifestyle has serious implications on the health of people and are known to cause diseases related to cardiovascular diseases, obesity, high blood pressure, etc. According to the World Health Organization, around 60% - 85% of people, worldwide, have adopted a sedentary life. According to Centre for Disease Control and Prevention, around 31 million adults aged over 50 years lives a sedentary life, and only 1 out of 4 US adults & 1 out 5 school student meets the guideline of physical activity. Heart disease is one of the leading causes of death in U.S., at least one person dies every 37 second due to cardiovascular disease, as reported by Centre for Disease Control and Prevention.

Asia Pacific is anticipated to expand at a significant growth rate during the forecast period. Change in lifestyle and the increase in obesity among the young population in Asia Pacific leads to hypertension and anxiety disorders. These are the major factors which are estimated to drive the demand for calcium channel blockers during the forecast period.

Competitive Landscape

The calcium channel blocker market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include ClearSynth, GlaxoSmithKline Plc., Pfizer Inc., AbMole Bioscience, Lupin Pharmaceuticals, Inc., Silvergate Pharmaceuticals Inc., Novartis AG, Covis Pharma BV, and Arbor Pharmaceuticals LLC. among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the calcium channel blocker globally.

Pfizer Inc.

Overview: Pfizer Inc. (Pfizer), incorporated on June 2, 1942, is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines that improve patients' lives. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology and rare diseases. EH includes legacy brands, branded generics, generic sterile injectable products, and biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. The Company sold its products in over 125 countries.

Product Portfolio: The Company's portfolio comprised of include internal medicine, vaccines, oncology, inflammation and immunology and rare diseases and others.

Why Purchase the Report?

  • Visualize the composition of the calcium channel blocker segmentation by drug class, route of administration, distribution channel, and region highlighting the key commercial assets and players.
  • Identify commercial opportunities in calcium channel blocker by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of calcium channel blocker- level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global calcium channel blocker report would provide an access to an approx. 63 market data table, 53 figures and 240 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Table of Contents

1. Global Calcium Channel Blocker Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Calcium Channel Blocker Market - Market Definition and Overview

3. Global Calcium Channel Blocker Market - Executive Summary

  • 3.1. Market Snippet by Drug Class
  • 3.2. Market snippet by Route of Administration
  • 3.3. Market Snippet by Distribution Channel
  • 3.4. Market Snippet by Region

4. Global Calcium Channel Blocker Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing Burden of Cardiovascular Diseases
      • 4.1.1.2. Changing Lifestyle of People
    • 4.1.2. Restraints:
      • 4.1.2.1. Side effects associated with these Drugs
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Calcium Channel Blocker Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Unmet Needs

6. Global Calcium Channel Blocker Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Calcium Channel Blocker Market - By Drug Class

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class Segment
  • 7.3. Market Attractiveness Index, By Drug Class Segment
      • 7.3.1.1. Dihydropyridine*
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
      • 7.3.1.2.1. Amlodipine
      • 7.3.1.2.1.1. Norvasc
      • 7.3.1.2.2. Nifedipine
      • 7.3.1.2.2.1. Procardia
      • 7.3.1.2.2.2. Adalat
      • 7.3.1.2.3. Felodipine
      • 7.3.1.2.3.1. Plendil
    • 7.3.2. Nondihydropyridines
      • 7.3.2.1. Verapamil
      • 7.3.2.1.1. Calan
      • 7.3.2.1.2. Isoptin
      • 7.3.2.2. Diltiazem
      • 7.3.2.2.1. Cardizem
    • 7.3.3. Benzothizepine
    • 7.3.4. Phenylalkylamine
    • 7.3.5. Others

8. Global Calcium Channel Blocker Market - By Route of Administration

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 8.3. Market Attractiveness Index, By Route of Administration
    • 8.3.1. Oral *
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Parenteral

9. Global Calcium Channel Blocker Market - By Distribution Channel

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
  • 9.3. Market Attractiveness Index, By Distribution Channel Segment
    • 9.3.1. Hospital Pharmacy *
      • 9.3.1.1. Introduction
      • 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 9.3.2. Pharmacy Stores
    • 9.3.3. Other

10. Global Calcium Channel Blocker Market - By Region

  • 10.1. Introduction
  • 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 10.3. Market Attractiveness Index, By Region
  • 10.4. North America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. U.S.
      • 10.4.6.2. Canada
      • 10.4.6.3. Mexico
  • 10.5. Europe
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6.
    • 10.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.7.1. Germany
      • 10.5.7.2. U.K.
      • 10.5.7.3. France
      • 10.5.7.4. Italy
      • 10.5.7.5. Spain
      • 10.5.7.6. Rest of Europe
  • 10.6. South America
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.6.6.1. Brazil
      • 10.6.6.2. Argentina
      • 10.6.6.3. Rest of South America
  • 10.7. Asia Pacific
    • 10.7.1. Introduction
    • 10.7.2. Key Region-Specific Dynamics
    • 10.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.7.6.1. China
      • 10.7.6.2. India
      • 10.7.6.3. Japan
      • 10.7.6.4. Australia
      • 10.7.6.5. Rest of Asia Pacific
  • 10.8. Middle East and Africa
    • 10.8.1. Introduction
    • 10.8.2. Key Region-Specific Dynamics
    • 10.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Global Calcium Channel Blocker Market - Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Global Calcium Channel Blocker Market - Company Profiles

  • 12.1. ClearSynth*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. GlaxoSmithKline Plc.,
  • 12.3. Pfizer Inc.
  • 12.4. AbMole Bioscience
  • 12.5. Lupin Pharmaceuticals, Inc.
  • 12.6. Silvergate Pharmaceuticals Inc.
  • 12.7. Novartis AG
  • 12.8. Covis Pharma BV
  • 12.9. Arbor Pharmaceuticals LLC
  • 12.10. Janssen Global Services, LLC

LIST NOT EXHAUSTIVE

13. Global Calcium Channel Blocker Market - Premium Insights

14. Global Calcium Channel Blocker Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us